 A message from Sideways Frequency |
|
BioStem Technologies Inc. (OTC: BSEM) is emerging as one of 2025’s most compelling MedTech growth stories — blending record-breaking financial performance with groundbreaking clinical results that could redefine the future of wound care. In August the company reported preliminary financial results for the second quarter ended June 30, 2025, revealing generated net revenue of $49.3 million. This was the sixth consecutive quarter of positive adjusted EBITDA with $2.5 million reported. BSEM also increased the cash balance to $30.8 million as of the end of the second quarter, an increase of $4.1 million from $26.7 million as of March 31, 2025. The company is pursuing a Nasdaq uplisting, a move expected to attract institutional investors and expand liquidity, while analysts at Zacks Small Cap Research have reaffirmed a bullish $25.50 price target, citing strong execution and accelerating growth. With 58 issued and 68 pending patents, BSEM’s innovation engine is powered by its proprietary BioRetain® technology — a patented process that preserves the natural structure and bioactivity of perinatal tissue to accelerate healing. New peer-reviewed data published in the International Journal of Tissue Repair demonstrated that BioRetain® allografts achieved a 53% healing probability in chronic diabetic foot ulcer patients, nearly doubling the 31% success rate of standard care. These results validate BSEM’s superior clinical performance and highlight the transformative potential of its regenerative medicine platform. The implications of these findings are significant. With DFUs affecting over two million patients annually in the U.S. and accounting for billions in healthcare costs, BioStem’s technology addresses a critical unmet medical need. Led by CEO Jason Matuszewski — recently named EY Entrepreneur of the Year 2025 — BSEM is rapidly scaling into a MedTech leader. With CMS national reimbursement secured for its flagship Vendaje AC®, ongoing pivotal trials for diabetic and venous leg ulcers, and community partnerships that elevate its national brand presence, BSEM is positioned to dominate multi-billion-dollar wound care markets! |
| This message is a paid advertisement for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency. Schaeffer’s Investment Research Inc. receives a fixed fee for each subscriber that clicks on a link in this email. Other than the compensation received for this advertisement sent to subscribers, Schaeffer’s Investment Research Inc. and its principals are not affiliated with BioStem Technologies Inc. (OTC: BSEM). Schaeffer’s Investment Research Inc. and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither Schaeffer’s Investment Research Inc. nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Schaeffer’s Investment Research Inc. to buy or sell any security. Schaeffer’s Investment Research Inc. has not evaluated the accuracy of any claims made in this advertisement. Schaeffer’s Investment Research Inc. recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on BioStem Technologies Inc. (OTC: BSEM) website for additional information. To stop receiving these emails, unsubscribe. |
Post a Comment
Post a Comment